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Novel method for detection of heterozygous truncating mutations in the
familial adenomatous polyposis and familial breast and ovarian cancer
genes, APC and BRCAJ, usJng a rapid screenlng assay in SacchaTOmyCeS
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¶le identificadon of novel gem-line mutationsintumor suppressor genes
presents a major difficultyindleir imidalcharacteri2adon, as well asinthe adaptadon of
reliableand effecdve approaches to climiCaldiagnosdcs. 刀le large size Of many of these
genesand dle factthat gem-line mutadons are heterozygous have comphcatedanalysis
based exclusively on nucleodde sequenclng. We have previously described a functional
assay to detect germ-line mutationsinp53, a genethat is affected primarily bymissense
1
mutadons, and whose funcdon as a transcripdonalactivator canbe testedinyeast.
Whnethefunctionalproperdes of other cancer suscepdbility genes　are not wen
understood, many of these aJTe disrupted primarily by truncahg mutations. Vhuallyall
mutadonsinthe colon cancer gene APC 2-5 and 80% of mutadons inthe breast cancer
predisposi血n gene BRCA1 6 consist of nonsense or frameshift mutadons, ぬading to
the development of screcnmg assays based onthe in vL'hlD Production of truncated
pepddes, so-caned PTr assays7-1 1･ These methodsare reliableand effective, but requlre
significant levels of techmiCalexpertiseandinterpretation of results. Here we describe a
simple yeast-based method, which makes use of homologous recombinadon　in
Sacchmvtnyces celleV血hze lD SeParatealklesandinvolvesthe production of a marker
fusion protein to test for trunc弧ing mutations.
The stop codon scan(SC assay) benefits from two advantages of yeast systems.
First die ability to synthesize fusion proteins withorotidine-5'-phosphate (OMP)
decarboxylase encoded bythe URA3　geneand second,the use of gap repalrand
homologous recombinadon to efficien止yinsert a PCR-generah:d sequenceintothis fusion
constructand separatethe products of different aneles･ The oudine of the assay lS
summarizedinFig･ 1･ We constructed a centromeric yeast expression vector, PCI-
HA(URA3)-2, withtwo selectable markers: LEU2and URA3 (codons 51267), which
complementthe genedc defects of the YPH499 strain, anowing growthinthe absence of
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leucineand uracn. 'me URA3 gene is driven bythe sb'ong PGK promoter, tagged atthe
N-terminus by hemagglu血in(HA),and interrupted by a BanHI site to　allow
inb･oducdon ofexogenous DNA fragments. To test whedler fusion of proteins tothe N-
teminus of URA3 preservesthe Ura'phenotype, 15 different coding sequen∝s of O･8-
3.4kbinsize, dedvedfrom 7 different genes wereinsertedin-frame.Allinsertions
demonstratedthe Ura'phenotype, conf+irmingthat dlis sekctable marker is not disrupted
by N-teminalfusion to a variety of proteindomains(data not shown). The Ura'
phenotype was dependent on use of the correct upstreim PrOmOterand translational
imidadon codon, as demonstrated by its loss fomowing plaαment of the URA3 fragment
inthe reverse orientadon, byinserdon of 4bpintothe BLmHI site, or byinserdon of
exogenous DNAfragments containingan　out10f frameinserdon orinthe reverse
orien血on･ Synthesis of the expected fun lengthURA3 fusion protein from Ura'colonies
was co血med by irmunoblo血ganalysis usnganti-HAantibody.As　predicted,
inserdon of out-of-frame sequencesinto PCI-HA(URA3)12 led to die expression of HA-
positive truncated fusion proteinsinUra- colomies (data not shown).
To test　the SC assay in detecting truncahg mutationsinBRCAl,the
coding sequence was dividedinto duee overlapping fragments, which wereamplified by
RT-PCRandinsertedin-frameintothe BLmHI site of the PCI-HA(URA3)-2 vector. 1me
resul血g constructs, pCIIBRla, band c, showed preservadon of the Ura'phenotype
following introduc丘oninto yeasL The plasmids were convertedintothe corrsponding
"gap vectors.., PCI-BRlag, pCIIBRlbg and pCIIBRIcg, by removlng most Ofthe
BRG41insert, leavlng 1(氾bp offlanking BRG41 sequence toallow for homologous
recombinadon (see Fig. lb　and Methods).　The　three corresponding BRCAl
fragments werethenamplified by RT-PCRfrom peripheralblood mononuclearceus of
padents withknown BRCAl truncahg mutadonsand controls. Cotransfomadon of
unpurified PCR productsand corresponding linearized gap vectorsinto yeast anowed
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homologous recombinadon　and growth　of leucine auxotrophs containing　the
recircularized plasmid. Twenty fiveindependent transformants were assayed for growth
inthe absen従Of uracil. Fouowing gap repair WithPCR products derived from control
lymphocytes, 88-100% of transformants were Ura', demonstra血g efficient homologous
recombination of the BRG4J fragmentand reconstitution of the URA3 fusion protein
Cral)le 1). The sman fracdon of Ura- b,ansformants is pnsunably due to infidelity of
the Taq DNA polymeraseand to recombinadon error, as described previouslyl･ In
comb.ast, PCR products derived from　the lymphocytes of padents with　known
heterozygous BRCAl mutadonsl 1 kd to 44-64% Ura+ transformants. These included
specimens from two padents (#231and #253) witha heterozygous 2bp deledon at codon
23 (the so-Called 185delAG mutation) (gap vector PCI-BRlag), one padent (寸秒9) witha
2bp dele血n at codon 327 (gap vector pCIIBRlbg), one pa也nt (#364) witha
nonsense mutadon at codon 563 (gap vector PCI-BRlbg),and one padent (#250) witha I
bpinsertion at codon 1756 (the so-cabd 5382insC muta血n) (gap vector pCLBRIcg).
Another 6 samplesthat only contained BRCAL polymorphismsll scored as wad-type
(Table 1). The dis廿ibution of Ura'and Ura- colomies dedved from specimens withor
without BRG41 tnmca血g mutadons was reproducibleand non-overlapping (Fig. 2),
demonstratingthe reliability of this assay for diagnostic purposes.
To testthe ability of the SC assay to detectunknown mutations, we chosethe
fammalpolyposis gene APC, which is inactivated exclusively (～93%) by truncating
mutadons located withinthe N-terminal60% of the coding sequence12･ This pordon of
theAPC CDNA was dividedinto two fragments, APCaand APCb, which containSthe so-
caned mutation cluster region (MCR)13, wasfu,ther dividedinto two ove,lapping
fragments, APCcand APCd.Asexpected, in-frame inserdon of these fragmentsinto
the BLmHI site of PCI-HA(URA3)-2 preservedthe Ura'phenotype. Wethenanalyzed
24individuals derived from sixunrelated famnies widl familialpolyposis (FA㌢) Crable 2).
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Analysis of the MCR region for 6 padents (individuals I-I from Families B, D, Eand F;
individualⅠ-7 from FamLy C; individualII-2 from Family A) who were clinically
diagnosed as affected, uslng gap V∝tOr PCI-APCbg, yielded yeast b.ansformants, half of
which retainedthe Ura'phenotype (m弧1 49%, range 38-60%), consistent withthe
presence of a heterozygous truncating mutaBon (Tabk 2). To idemifythe precise
locadon of each mutadon, gap repau assays wereperformed using dleintEmalgap vectors,
PCI-APCcg and pCIIAPCd (NdeIINsll digest):individualⅡ-2 from Family Åand
individualⅠ-I from Fam止y B, scored posi丘vefor mutadons widlinfragment APCc, but
not APCd, whereasthe converse was true for individualIl7from Farnily Cand
individuals Ill from Farnilies D-F. Thisanalysis was extended tothe remaJnlng 18
members of these families, idemifying 5individuals as having heterozygous trunc姐ng
mutadons withinthe same fragment asthe proband (Table 2).　Sixindependent Ura-
colonies were pooled and subjected to direct nucleotide sequenclng. ne SeParadon of
APCalleles resulting fromthe gap repair assay made it possible to specificdlyanaly2X:the
mutaJltallele, avoidingthe difficul血s inherentinsequenclng heterozygous mut加ions.
All specimens scored as positive by SC assay were found to have truncabng APC
mutadons: a 4bp dekBdon at codon 929 (3765de14)inFamily A, a lbpinsertion at codon
938 (2831insT) in Fandy B, a 2bp deldon atcodon 1249 (3765de12)inFamily C, a 5bp
deledon atcodon 1309 (3945de15)inbothFamilies Dand E,and a lbp deletion at codon
1322 (3983delA)inFamily F gable 2).Analysis of odler members from each fanny
demonstrated a complete concordance betweenthe results of the SC assayand direct
sequencinganalysis Crable 2).
The mutadonalanalysisthat we describe here is comparable in its efficacy to
previously described PTr teclmiquesthatinvolve PCR-amplification of gene fragments,
fonowed by in vi細tranSCription-tranSladon and resolution of encoded pepddes by SDS-
PAGE. However,the yeast-based SC assay provides a number of important techmiCal
5
advantages compared to dleSe加viqD, gel-based assays.Amongtheseare (i)the
ability to analyze larger (-3.5kb) DNAかagments, which托duccsthe number of PCR
reiK:也ons required to scananemire gene for trunca血g mutadons, (ii)the abnity to
detect mutationsthat arise adjacent tothe PCR-primers, which minimiZeSthe overlap
required between fragments, (ih)the separation of aneles, which gready simplifies
conflrmadon of hetero野gOuS mutadons by nucleo丘de sequencing, (iv) avoidance of
the requirement for radioisotopes and for protein gel-electrophoresis. From a technical
standpoint,the SC assay requires few mmipuladonsand dle血Ie required toperformthe
assay (four days) reflectsthat required 也 clearly visuali2XB yeaLSt COlomies after sequemial
plahg on leucineand uracn derlCient plates. ne use of a mutadonalscreenmg test
based onthe detection of trunc血ng mutationsalso has important advantagesin血e
adaptadon of such approaches to chicaldiagnostics. Proteintruncabng mutations
comprisethe majority ofinactiV血g mutadons for a number of important cancer
predisposition genes,including BRC41, BRCA2, APC,mismatch repair genes,and
potentiany AIM. FurdlemOre,the difficultyininterpre血g　miSsense mutations
precludestheir use in most climiCaldiagnos血S. ¶le SC assaythus provides a rapidand
reliable testthat can be readdy adapted to detect heterozygous truncabng muta丘onsin
Cancer predisposition genesand other genes imphcatedinhuman disease.
Melhods
Plasmid consLT'uCtion. The plasmid PCI-HA(URA3)12 was constructed as
fonows: a fhgment spanming nucleotide-number (nL) 423 to 1239 of the plasmid
pRS31614 (GenBank UO3442), which contains URA3 coding sequence from codon 5 10
the naturalternhadon codon, wasamplified by PCR using a set of primers contalnlng a
BmnHI site or a BgaI site atthe 5. end. The BmnHI/Bgul fragment was insertedin-frame
inbthe BLZmHI site of the plasmid PRS-PGK15 10 produce PCI-HA(URju). This vecto,
was digested withNsltand PstT and religated to produce PCIIHA(URA3)-2 (Fig. 1a)･
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¶lr綻fragments spaming nt. 96 to 908 (BRCAla), nL 789 to 4214 (BRCAlb)and nL
4089 to 5708 (BRCAIc) of the BRG4J CDNA (GenBank U14680), wereamplified
and insertedin-frameintDthe BLmHI site of the PCI-HA(URA3)-2 to produ∝ PCI-BRla,
PCI-BRlband PCI-BRIG, respecdvely (Fig･ lb)･ Four血agments spanning nt･ 19 to
1977 (APCa), nt 1978 to 5256 (APCb), nt. 1978 to 3570 (APCc)and nL 3571 to 5256
(ApCd) of the APC CDNA (GenBank M74088), were amplified and insertedin-frame
intothe BLmHI site of PCI-HA(URA3)-2 b produce PCI-APCa, PCI-APCb, PCI-APCc
and PCI-APCd, respecdvely (Fig. lb).仙the vectors described above resultina Ura'
phenotype, followingintroduction　into YPH499 strain･ The gap vectors, PCI-BRlag,
PCI-BRlbg, PCI-BRIcg, PCI-APCag, PCI-APCbgand PCI-APCcg (Fig･ lb)are
idendcalto PCI-BRla, PCI-BRlb, PCI-BRIG, pCIIAPCa, PCI-APCband PCI-APCc,
respectively, exceptthatthe centralportions oftheinserted fragments, BRCAla･
BRCAlb, BRCAIc, APCa, APCband APCc, between nt. 183 to 827, nt. 888 to 4111,
nL 4215 to 5609 (GenBaJik U14680), nt. 109 to 1899, nt. 2054 to 5201 and nt. 2086 to
3489 (GenBank M74088), were replaced bythemique resdction sites, BgnI,
SLuuBamHI/Smd, Bg瓜, BgⅢ, Nsll and BguI, respectively･ A皿the gap vectors
except pCIIAPCbg were produced by PCR using ExTaq (TAKARA) andthe original
plasmids widl fd-lengdlinsertion as templates, followed byligation uslngthe unique
restricdon sites described above and transformation of E. coli (DH5α). The PCI-APCbg
was obtained by removingthe centralpordon of APCb丘agment of the PCI-APCb using
two Nsll sites.
PCR. For BRG41and APCanalysis, genomic DNAand/or totalcenular
RNA was isolated from EBV-immortalized cenlines or peripheralblood mononuc血r
cens. CDNA was syndleSized by using a First-Sb･and CDNA SynthesisKit (Pharmacia)･
BRCAla-Cand APCa (see Fig. lb) were amplified from cDNA･ BRCAband APCb-d
were amplified from genomic DNA･ Primers foramplificadon of BRCAl fragments were
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5 ㌧GAAAmAmGAACAGAAAGAA-3 - and
5㌧ACCCTGATACmCTGGATG-3' for BRCAla,
5 LCCCAGATCTGCTGCTFGTGAAr I Tl lCTGAG-3 land
5'-CCCAGATCTTjuGTrrGAATCCATGCTITG-3- for BRCA 1 b,and
5 I-ATGAGGC ATCAGTCTGAAAGC-3 - and
5 I-GTAGTGGCTGTGGGGGATCT-31 for BRCA Ic.
Primers for amplificadon of APCfragments were
5 I- ATGGCTGCAGCTrCATATGAT-3 I






5'- GTCCATrATCITITIICACACG-3- for APCd. A皿PCR fhgments were obtained by
using ExTaq polymerase CrAKjuA). btails of the PCR parametersare avahble from
the authors upon request.
YeasL LTanSfonnaLion. The yeast sb･ainusedindds study was YPH499
(AL4 TL"nag-52, lys2-801andw,.de2-101ochre,坤1A63, his3A200,leu2Al) (Sb,atagene).
Competent yeast Gens were prepared bylithium acetate恥iOAc) b'eatment of the strain
culturedinYPD hquid mediumland were stored at -80oCinthe presence of 5% DMSO
until use. Frozen competent yeast retainhigh transformadon efficiency for at least　three
months. Gap repair assays Were performed by cob･ansfomation of unpurified PCR
product (～200ng)and lineari2ed gap vector (～30ng) bythe LiOAc method16 withminor
modificadonsl･ Toanaly2ethe PCR fragments, BRCAla, BRCAlb, BRCAIc, APCa,
APCb, APCc,and APCd, linearized gap vectors, PCI-BRlag (Bg皿I digest), pCLBRlbg
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(BLmHI/Smd digest), PCI-BRIcg (BgEI digest), pCIIAPCag (Bgnl digest), pCI-
APCbg (NsIT digest), PCI-APCcg (BguI digest), and PCI-APCg (NdeIINsll digest) were
used, resp∝dvely･ Transformants were selected on synthedc complete medium (SC)
lacking leucine (SC-Leu); 25 transformants werethen assayed for die Ura'phenotype by
growdl On SC lacking leucineand uracil (SC-Leu-Ura). Ⅳ morethan　85%　of
transformants are Ura',the sample is scored as homozygous wad-type, whereas if an
transformants ale Ura~,the sample is scored as homozygous mutant. If 40-50% of
colomies are Ura+,the samples is scored as heterozygous for a truncation mutant.
Seq〟enctng･ YeGLSt DNA extraction from pooled Ura- tranSformants was
descdbed previously17･ TemplateAPC打agments wereamplined as described above and
were sequenced using CircumVentTM ThermalCycle Dideoxy DNA Sequencing Kit (New
hgland Biohbs)･ Appropriate APC specific oligonucbtides were used as sequencing
primers after end-labeled by l7-33p] dATP.
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Fig. 1 Schematic representation of SC assay.
a. PCI-HA(URA3)-2 vector. In-frameinsertion of a coding sequence of interest
intothe unique BamHI由te resultsinconstitutive expression ofanHA-tagged URA3
fusion protein, driven fromthe PGK (3-phosphoglycerate kinase) promoter. h addition,
the vector containSthe PGK terminator downstreiLm Ofthe URA3鉦agment,the LEU2
gene as a second selectable marker, and CBNand ARS for stable low copy number
rephcation. The derived gap vector lacksthe ∝ntralpordon oftheinserted fragment,
which can be replaced by a PCR-generated fragmentinserted by homologous
recombinadon, usingthe remainingflanking sequences.
b. Sequences of BRG41and APC chosenforanalysis. CDNA or genomic
fragments denoted BRCAla,Cand APCa-d wereinserted in-frame intothe BamHI site
of PCI-HA(URA3)-2, producing plasmids PCI-BRla, band c, and PCI-APCa, b, c and d.
Plasmids, pCIIBRlag, bg and cg,and PCI-A陀ag, bland cg, are gap vectors.
C. Schemadc representation of SC assay. 1. PCR amplification of CDNA or
genomic fhgment containing w止d-type (W¶ or hncated mutaJlt (mt; nonsense Or
frameshift) is combined widlthe appropriate gap vector, Which contains l00bpflanking
the PCRfragment to anow 氏)r efficient homologous recombinadon. 2. transformation
of leu2~and war defident yeast withthe PCR productand gap vector yields leucine
prototropic transformantsthat haveundergone recirculari2adon of the plasmid fouowing
homologous recombinadon･ 3･ selecdon ofLeu'prototroph fonowing repla血ginthe
absen∝ of uracu distinguishes Ura'prototrophs (Wild-typeinserted sequence)from Ura-
auxotrophs (truncatiOn mutation). OMPD, orotidine-5■-phosphate (OMP) decarboxylase.
13
4. Representadve SC assay for BRCAI (fragment BRCAlb) and APC
(&agment APCb), showing growthof yeast b･anSformantsinthe absence of uracil･ In
bothcases, die left half-plate represents a specimen derived from a pabent witha
heterozygous trunca血g mutation,andthe dght half-plate is a control sample･
Fig･ 2　Distribution of tJra+ colomies deriyed from specimenswithwiLd･
type BRCAL　帥d Arc or containing a heterozygous truncating
mutation.
Results of the SC assay are shown for 75 specimens for which presence (closed
bar) or absence (open bar) of a truncating mutadon was connmed by nucleotide
sequenclng･ Values in parenthesisindicate mean ± Standard deviation･
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Table 1 SC assay for βFICA7 in women with early･onSet breast cancer
SC assay (% Ura'cdonles)　　　　　　　　　　Mutatjon
BRCAl fragment 1 a 1 b 1 c Sequenco Location
codonS　　　　　　　1 I 263　　　　224 - 1365　　1324. 1863































CGA to T丘A -nonsonso1
codon 327 (Oxon 1 1)
codon 23 (Oxon 2)
codon 1 756 (Oxon 20)
codon 23 (Oxon 2)
codon 563 Eexcln ll)
AJl pabnts aro women with broast cancer boforo tho ago 30 and havo been charactedzed for BF7CAl mutadons previou$ly
(ref･1 1)･ Lmdon o‖〕RCAl fragment was hldicatod ln Fig･ 1 ･ Bc･xed number indicates existence of trunca蜘1g mutation in
examined DNA fragment by SC assay･ gDNA･ genomlc DNA; ND, not detormjned; WT. dld-type jn the entire codjng
Sequenco. The mutations detocted ln Pt.231 and Pt. 253 aro known aS 185delAG. The mutation detected in Pt. 250 is known
BS 5382insCI Theso mutations aro prevalent in the Ashkenazi Jedsh population.
Table 2
Table 2 SC assay for APC mutations in 6 FAPfamilies･
SC as組y (% Ura'colonies)
APC fragment b c d Sequ ence
Codon$　　　　　　　　654- 1748　654- 1184 1185 ･ 1748























[蚕】　1 00　　　T insonion (frameshiq
92　　　　　N D WT
1 00 ND WT
ND 1 OO　　　　　　　　　Ⅵ汀

























[垂I A deletion (frameshift)
92　　　　　　　　　　WT
Location
ccdon 929 - 930 (Exon 15)
codon 929 - 930 (Exon 15)
codon 938 (Exon 1 5)
codon 1249 I 1250 (Exon15)
codon 1249 - 1250 (Exon15)
codon 1249 - 1250 (Exon15)
codon 1249 I 1250 (Exon15)
codon 1309 -1311 (Exon 15)
codon 1309 -131 1 (Exon 15)
codon 1309 -1311 (Exon 15)
codon 1322 (Exon 15)
AJHndividuals in the 6 FAPfarnllies aro Japaneso. Locaぬn of Ape fragmont was indicated in Fjgl 1･ Boxod numbor
indbates existenco of truncating mutation in examined DNA fragmont by SC assay. gDNA. gonomic DNA; ND, not
dotomlined; WT, wild-typo ln tho examined ceding sequence.
D_
>∩a
